FI105275B - Monoklonala antikroppar mot hepatit C-virus - Google Patents
Monoklonala antikroppar mot hepatit C-virus Download PDFInfo
- Publication number
- FI105275B FI105275B FI924641A FI924641A FI105275B FI 105275 B FI105275 B FI 105275B FI 924641 A FI924641 A FI 924641A FI 924641 A FI924641 A FI 924641A FI 105275 B FI105275 B FI 105275B
- Authority
- FI
- Finland
- Prior art keywords
- hcv
- hepatitis
- cell line
- virus
- antibodies
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 44
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000009257 reactivity Effects 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 208000002672 hepatitis B Diseases 0.000 description 12
- 208000005252 hepatitis A Diseases 0.000 description 11
- 210000005228 liver tissue Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000008279 sol Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
- G01N2474/20—Immunohistochemistry assay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (6)
1. Hybridomcellinje, kännetecknad av att den förmär producera antikroppar med samma immunoreak- 5 tivitet mot hepatit C-virus (HCV) proteiner som de antikroppar som produceras av cellinjen som deponerats vid ECACC under deponeringsnr 91101711.
2. Hybridomcellinje enligt patentkrav 1, kännetecknad av att den är cellinje nr 91101711 som 10 deponerats vid ECACC.
3. Antikropp, kännetecknad av att den har samma immunoreaktivitet mot hepatit C-virus (HCV) proteiner som de monoklonala antikroppar som produceras av cellinjen som deponerats vid ECACC under deponeringsnr 15 91101711.
4. Antikropp enligt patentkrav 3, kännetecknad av att den är den monoklonala antikropp som kan erhällas ur cellinje nr 91101711 som deponerats vid ECACC. 20
5. Förfarande för att detektera hepatit C-virus (HCV) i ett prov, kännetecknatav att provet ,.,: bringas i kontakt med en antikropp enligt patentkrav 3 el- ,: ler 4, varefter närvaron av immunkomplex som bildats de- |'r tekteras och pä basen av det bestäms närvaron av HCV.
6. Testförpackning för att utföra förfarandet en- • · · ligt patentkrav 5, kännetecknad av att den in- • « · *· ‘ί nehäller en fast fas pä vilken antikroppar som producerats 111 V : av cellinjen som deponerats vid ECACC under deponeringsnr 91101711 immobiliserats och medel för att detektera even- 30 tuella immunkomplex som bildas mellan antikropparna pä den ·1'1: fasta fasen och HCV, som eventuellt finns närvarande i • M . 1. provet, efter att provet bringats i kontakt med den fasta f J· / fasen. I · I < · « I · I « · « « • · ·
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91202659 | 1991-10-15 | ||
| EP91202659 | 1991-10-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI924641A0 FI924641A0 (fi) | 1992-10-14 |
| FI924641A FI924641A (fi) | 1993-04-16 |
| FI105275B true FI105275B (sv) | 2000-07-14 |
Family
ID=8207945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI924641A FI105275B (sv) | 1991-10-15 | 1992-10-14 | Monoklonala antikroppar mot hepatit C-virus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5595868A (sv) |
| EP (1) | EP0537856B1 (sv) |
| JP (1) | JP3335387B2 (sv) |
| KR (1) | KR100238559B1 (sv) |
| AT (1) | ATE162553T1 (sv) |
| AU (1) | AU670541B2 (sv) |
| CA (1) | CA2080548C (sv) |
| DE (1) | DE69224134T2 (sv) |
| ES (1) | ES2114547T3 (sv) |
| FI (1) | FI105275B (sv) |
| ZA (1) | ZA927837B (sv) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2049679C (en) * | 1990-08-24 | 2005-06-21 | Sushil G. Devare | Hepatitis c assay utilizing recombinant antigens |
| US5753430A (en) * | 1990-11-07 | 1998-05-19 | Abbott Laboratories | Monoclonal antibodies to hepatitis C virus and method for using same |
| EP0556320B1 (en) * | 1990-11-07 | 1999-03-24 | Abbott Laboratories | Monoclonal antibodies to hepatitis c virus and method for using the same |
| JP3217600B2 (ja) * | 1994-07-12 | 2001-10-09 | 株式会社先端生命科学研究所 | 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ |
| CN1044384C (zh) * | 1994-08-25 | 1999-07-28 | 中国药品生物制品检定所 | 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体 |
| US5849800A (en) * | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
| CA2316130A1 (en) * | 1999-08-19 | 2001-02-19 | Masanori Fukui | Method for detection or determination of hcv core antigens and reagent for detection or determination for use therein |
| US7022323B2 (en) * | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| US20030232745A1 (en) * | 2001-06-26 | 2003-12-18 | Olson William C. | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection |
| US7049060B2 (en) * | 2001-11-05 | 2006-05-23 | Ortho-Clinical Diagnostics, Inc. | HCV anti-core monoclonal antibodies |
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| ES2456961T3 (es) | 2007-02-21 | 2014-04-24 | University Of Massachusetts | Anticuerpos humanos contra el virus de la hepatitis C (VHC), usos de los mismos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049686C (zh) * | 1987-11-18 | 2000-02-23 | 希龙股份有限公司 | 非ａ和非ｂ肝炎病毒的诊断及疫苗 |
| US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
| KR0185373B1 (ko) * | 1989-03-17 | 1999-05-01 | 로버트 피. 블랙버언 | Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용 |
| EP0445801A3 (en) * | 1990-03-08 | 1992-07-01 | Kuraray Co., Ltd. | Peptide and its use |
| JPH0436185A (ja) * | 1990-03-28 | 1992-02-06 | Kyowa Hakko Kogyo Co Ltd | 融合抗原ポリペプチド |
| ZA912040B (en) * | 1990-03-30 | 1991-12-24 | Akzo Nv | Peptides immunochemically reactive with antibodies directed against hepatitis non-a,non-b virus |
-
1992
- 1992-10-12 ZA ZA927837A patent/ZA927837B/xx unknown
- 1992-10-14 ES ES92203144T patent/ES2114547T3/es not_active Expired - Lifetime
- 1992-10-14 CA CA002080548A patent/CA2080548C/en not_active Expired - Fee Related
- 1992-10-14 AT AT92203144T patent/ATE162553T1/de not_active IP Right Cessation
- 1992-10-14 FI FI924641A patent/FI105275B/sv active
- 1992-10-14 DE DE69224134T patent/DE69224134T2/de not_active Expired - Lifetime
- 1992-10-14 EP EP92203144A patent/EP0537856B1/en not_active Expired - Lifetime
- 1992-10-15 JP JP27712892A patent/JP3335387B2/ja not_active Expired - Fee Related
- 1992-10-15 KR KR1019920019092A patent/KR100238559B1/ko not_active IP Right Cessation
- 1992-10-15 AU AU27079/92A patent/AU670541B2/en not_active Ceased
-
1995
- 1995-08-14 US US08/514,982 patent/US5595868A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR100238559B1 (ko) | 2000-01-15 |
| JP3335387B2 (ja) | 2002-10-15 |
| CA2080548C (en) | 2003-07-01 |
| CA2080548A1 (en) | 1993-04-16 |
| KR930008155A (ko) | 1993-05-21 |
| DE69224134D1 (de) | 1998-02-26 |
| AU2707992A (en) | 1993-04-22 |
| AU670541B2 (en) | 1996-07-25 |
| EP0537856B1 (en) | 1998-01-21 |
| ATE162553T1 (de) | 1998-02-15 |
| ES2114547T3 (es) | 1998-06-01 |
| FI924641A (fi) | 1993-04-16 |
| FI924641A0 (fi) | 1992-10-14 |
| JPH05260960A (ja) | 1993-10-12 |
| EP0537856A1 (en) | 1993-04-21 |
| ZA927837B (en) | 1994-03-11 |
| US5595868A (en) | 1997-01-21 |
| DE69224134T2 (de) | 1998-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4487829A (en) | Production and use of monoclonal antibodies against adenoviruses | |
| FI105275B (sv) | Monoklonala antikroppar mot hepatit C-virus | |
| JP4118955B2 (ja) | Ｂ型肝炎モノクローナル抗体 | |
| US6623921B2 (en) | Method for measurement of hepatitis C virus | |
| US4910131A (en) | Idiotype and anti-idiotype antibodies useful in virus detection | |
| AU632271B2 (en) | Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver | |
| JP7454546B2 (ja) | Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対して特異性を有する抗体及びその診断目的のための使用 | |
| CN112384530B (zh) | 戊型肝炎病毒orf2i蛋白的表位肽 | |
| AU1362792A (en) | Monoclonal antibodies to putative hcv envelope region and methods for using same | |
| AU682335B2 (en) | Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virus | |
| JP3292728B2 (ja) | Ｃ型肝炎ウイルスに対するモノクローナル抗体およびその使用法 | |
| Dawson et al. | Monoclonal antibodies to hepatitis A virus | |
| Whittaker et al. | Plasma membrane orientation of simian virus 40 T antigen in three transformed cell lines mapped with monoclonal antibodies | |
| WO1986003498A1 (en) | Monoclonal antibodies and their use | |
| JPH10506382A (ja) | 急性および慢性ｃ型肝炎ウイルス感染の鑑別診断のための方法および組成物 | |
| EP0409883A1 (en) | MONOCLONAL ANTIBODIES TO ENTEROVIRUSES. | |
| Ben-Porath et al. | Monoclonal antibodies as diagnostic probes in the etiology of hepatitis | |
| EP0186371A2 (en) | Monoclonal antibodies specific to antigens of Hepatitis B virus | |
| KR20240097988A (ko) | 신규한 일본뇌염 바이러스 항원과 일본뇌염 특이 항체 및 이의 용도 | |
| JPH0797398A (ja) | Ｃ型肝炎用検査薬およびｃ型肝炎ウイルス抗原ペプチド | |
| JPH04505253A (ja) | 血液中のニューモシスティスカリニ抗原の存在を検出する方法およびシステム | |
| JP2009142269A (ja) | ヒトＩｇＧのＦｃを含有するタンパク質の測定試薬 | |
| DD268162B1 (de) | Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes immunglobulin m (igm) | |
| WO1990000404A1 (en) | Enrichment of antigen-specific polyclonal antibodies through selection of immortal hybrid cells |